Drug Profile

Research programme: immuno-oncology therapeutics - Dragonfly Therapeutics

Latest Information Update: 28 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dragonfly Therapeutics
Class Antineoplastics; Immunotherapies; Natural killer cell therapies
Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Natural killer cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Feb 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
10 Aug 2020 Celgene exercises its option to in-license fourth TriNKET™ immunotherapy drug candidate for Haematological cancer from Dragonfly Therapeutics
20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com